Treatment and prognosis of multiple primary malignant neoplasms complicated with renal cell carcinoma

  • Min QIU ,
  • Yan-yan LIAN ,
  • Min LU ,
  • Bin-shuai WANG ,
  • Xiao-jun TIAN ,
  • Jian LU ,
  • Cheng LIU ,
  • Shu-dong ZHANG ,
  • Min JIANG ,
  • Lu-lin MA
Expand
  • 1. Department of Urology, Peking University Third Hospital, Beijing 100191, China
    2. The Third Clinical Medical College of Beijing University of Chinese Medicine, Beijing 100029, China
    3. Department of Pathology, Peking University Third Hospital, Beijing 100191, China
    4. Department of Oncology, Dong Fang Hospital of Beijing University of Chinese Medicine, Beijing 100078, China

Received date: 2022-03-31

  Online published: 2022-08-11

Abstract

Objective: To investigate the treatment and prognosis of multiple primary malignant neoplasms (MPMN) complicated with renal cell carcinoma (RCC), and to make risk stratification. Methods: A retrospective study of 27 cases of MPMN with RCC in two centers, including the different tumors of MPMN, specific treatment methods, and the interval between primary cancers. At the same time, the survival conditions, including recurrence, metastasis and survival, were followed up for statistical analysis. The interval between the two kinds of primary cancer within 6 months was simultaneous MPMNs, and more than 6 months was metachronous MPMNs. For simple risk stratification of cases, as long as one of the MPMNs had a stage Ⅲ or higher malignancy, which was defined as high risk. Results: Among the 27 patients, 20 were male and 7 were female, with age at the time of diagnosis was 42-82 years, with an average age of (61.3±11.7) years. The age at the diagnosis of renal cancer was 43-87 years, with an average age of (66.0±11.3) years. There were 21 cases with duplex primary malignant neoplasms, 4 cases with triple primary malignant neoplasms, and 2 cases with quadruple primary malignant neoplasms. The interval between first cancer and second cancer was 0-360 months, with a median of 18 months. There were 17 cases of metachronous multiple primary malignant neoplasms and 10 cases of simultaneous multiple primary malignant neoplasms. The most common system of MPMN with comorbid RCC involved urologic system, digestive system and respiratory system. The most common locations of MPMN with comorbid RCC were bladder cancer, lung cancer and colon cancer. Follow-up time calcu- lated from the last cancer was 2-156 months, with a median of 32 months. And 14 cases survived and 13 cases died, with 11 cases being tumor related. Tumor stage was the risk factor of prognosis. Any kind of tumor stage in stage Ⅲ or above had a relatively poor prognosis. Conclusion: MPMN complicated with RCC is relatively rare. Standard treatment should be used for each cancer type during the treatment process. The prognosis mainly depends on the highest stage of each tumor. Simple risk stratification shows that the prognosis of the high-risk group is worse. This simple stratification method may be helpful to predict the prognosis.

Cite this article

Min QIU , Yan-yan LIAN , Min LU , Bin-shuai WANG , Xiao-jun TIAN , Jian LU , Cheng LIU , Shu-dong ZHANG , Min JIANG , Lu-lin MA . Treatment and prognosis of multiple primary malignant neoplasms complicated with renal cell carcinoma[J]. Journal of Peking University(Health Sciences), 2022 , 54(4) : 680 -685 . DOI: 10.19723/j.issn.1671-167X.2022.04.016

References

1 Matzkin H , Braf Z . Multiple primary malignant neoplasms in the genitourinary tract: Occurrence and etiology[J]. J Urol, 1989, 142 (1): 1- 12.
2 宋航, 邱敏, 卢剑, 等. 合并肾癌的多原发癌诊断与治疗[J]. 北京大学学报(医学版), 2016, 48 (5): 926- 929.
3 Warren S , Gates O . Multiple primary malignant tumor A surgery of the literature and statistical study[J]. Am J Cancer, 1932, 51 (16): 1358- 1414.
4 Moertel CG , Dockerty MB , Baggenstoss AH . Multiple primary malignant neoplasms. Ⅰ. Introduction and presentation of data[J]. Cancer, 1961, 14, 221- 230.
5 Feller A , Matthes KL , Bordoni A , et al. The relative risk of second primary cancers in Switzerland: A population-based retrospective cohort study[J]. BMC Cancer, 2020, 20 (1): 51- 65.
6 Tanjak P , Suktitipat B , Vorasan N , et al. Risks and cancer associations of metachronous and synchronous multiple primary can-cers: A 25-year retrospective study[J]. BMC Cancer, 2021, 21 (1): 1045- 1054.
7 El-Taji O , Al-Mitwalli A , Malik F , et al. Secondary neoplasms of the urinary bladder-clinical management and oncological outcomes[J]. Transl Androl Urol, 2021, 10 (6): 2427- 2434.
8 Beisland C , Talleraas O , Bakke A , et al. Multiple primary malignancies in patients with renal cell carcinoma: A national population-based cohort study[J]. BJU Int, 2006, 97 (4): 698- 702.
9 Koh HM , An HJ , Ko GH , et al. Identification of myoferlin expression for prediction of subsequent primary malignancy in patients with clear cell renal cell carcinoma[J]. In Vivo, 2019, 33 (4): 1103- 1108.
10 Tian X , Xu WH , Wu JL , et al. Clear cell papillary renal cell carcinoma shares distinct molecular characteristics and may be significantly associated with higher risk of developing second primary malignancy[J]. Pathol Oncol Res, 2021, 27, 1609809.
11 邱敏, 卢剑, 马潞林, 等. 透明细胞乳头状肾细胞癌的诊治经验[J]. 中华泌尿外科杂志, 2016, 37 (9): 655- 659.
12 Heo J , Noh O K , Oh Y , et al. Second primary cancer after liver transplantation in hepatocellular carcinoma: A nationwide population-based study[J]. Hepatol Int, 2017, 11 (6): 523- 528.
13 Wang L , Wang H , Wang T , et al. Analysis of polymorphisms in genes associated with the FA/BRCA pathway in three patients with multiple primary malignant neoplasms[J]. Artif Cells Nanomed Biotechnol, 2019, 47 (1): 1101- 1112.
14 Peng L , Zeng Z , Teng X , et al. Genomic profiling of synchronous triple primary tumors of the lung, thyroid and kidney in a young female patient: A case report[J]. Oncol lett, 2018, 16 (5): 6089- 6094.
15 Keegan THM , Bleyer A , Rosenberg AS , et al. Second primary malignant neoplasms and survival in adolescent and young adult cancer survivors[J]. JAMA Oncology, 2017, 3 (11): 1554- 1557.
16 Cho YY , Lim J , Oh C , et al. Elevated risks of subsequent primary malignancies in patients with thyroid cancer: A nationwide, population-based study in Korea[J]. Cancer, 2015, 121 (2): 259- 268.
17 Joung JY , Kwon W , Lim J , et al. Second primary cancer risk among kidney cancer patients in Korea: A population-based cohort study[J]. Cancer Res Treat, 2018, 50 (1): 293- 301.
18 Etiz D , Metcalfe E , Akcay M . Multiple primary malignant neoplasms: A 10-year experience at a single institution from Turkey[J]. J Cancer Res Ther, 2017, 13 (1): 16- 20.
Outlines

/